Study | Patient reported outcomes | Progression | Lesion volume | Hip survivorship | |
---|---|---|---|---|---|
 | Outcome |  |  |  |  |
Hernigou et al. [35] | HHS (13Â years) | Improved compared to baseline score (88 vs 70)^ | Â | Decreased lesion volume (12 cm3 vs 26 cm3)^ | 17.6% conversion rate to THA at 13Â years follow up |
Wang et al. [9] | HHS | Improved compared to baseline score (83.7 ± 10.34 vs 71.2 ± 6.56)* | 23.7% rate of progression to higher ARCO class |  | 11.8% conversion to THA at 27.6 months |
Gangji et al. [2] | Lequesne index | Improved compared to CD (SC group 4.8 ± 1.8, CD group NR)* | Decreased progression (23.1% vs 72.7%)* | Decreased lesion volume at 24 months (SC group volume decreased 42%, CD group volume decreased 1%)*, no improvement at 60 months (SC group volume decreased 42%, CD group volume decreased 22%)# | No improvement in hip survivorship (57.2 months vs 50.2 months) |
 | VAS pain | Improved compared to CD (SC group 20.8 ± 7.7, CD group NR)* |  |  |  |
 | WOMAC | No improvement compared to CD (raw score NR) |  |  |  |
Sen et al. [14] | HHS (12 months) | Improved compared to CD (83.65 ± 8.04 vs 76.68 ± 13.86)* |  |  | Improved hip survivorship (51.85 ± 0.15 weeks vs. 46.62 ± 2.34 weeks)* |
Zhao et al. [8] | HHS ARCO 1C,2B,2C (60Â months) | Improved compared to CD (raw score NR)* | Decreased progression (3.8% vs. 22.7%)* | Decreased lesion volume in ARCO 2B (6.5% vs 13.3% of FH), and ARCO 2C (13.8% vs 29.3%)* | Decreased rate of conversion to THA/vascularized bone graft in the SC group compared to CD (3.7% vs. 22.7%)* |